Clinical trials: Ranibizumab
Choroidal Neovascularization
Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
The purpose of study is to determine if Lucentis combined with imatinib mesylate will help treatment in patients with newly diagnosed choroidal neovascularization.
- Trial name
- NCT00403156
- Testing
- Imatinib Mesylate /Ranibizumab
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Ischemic Central Retinal Vein Occlusion
Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal…
- Trial name
- NCT00406471
- Testing
- Ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Greater Houston Retina Research
Polypoidal Choroidal Vasculopathy
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 1.0 or 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and…
- Trial name
- NCT01469156
- Testing
- ranibizumab 0.5 or 2.0 mg/0.05 cc
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Southeast Retina Center, Georgia
Central Retinal Vein Occlusion
Retinal Blood Flow in Response to an Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion (CRVO)
Ranibizumab (Lucentis, Genentech) is an off-label drug used for the clinical treatment of central retinal vein occlusion, which is one of the most common retinal vascular disorders.
- Trial name
- NCT01303276
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Macular Degeneration, Choroidal Neovascularization
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
Evaluation of Dosing Interval of Higher Doses of Ranibizumab for patients with wet age-related macular degeneration (AMD).
- Trial name
- BGB/IST (NCT00533520)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Brandon G. Busbee, MD
Recalcitrant Wet Age-related Macular Degeneration
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept.
- Trial name
- RESCUE (NCT01972763)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Northern California Retina Vitreous Associates
Diabetic Macular Edema, Cataract
Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs.
- Trial name
- STAMP (NCT03832179)
- Testing
- Bevacizumab, Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bay Area Retina Associates
Neovascular Age-Related Macular Degeneration
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
- Trial name
- NCT01926977
- Testing
- Ranibizumab 0.5mg, Aflibercept 2.0mg
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Arshad Khanani
Diabetic Macular Edema
Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (VEGF) Treatment of Diabetic Retinopathy
The study will investigate changes in the structure and function of blood vessels in the front and back of the eye following laser and anti-VEGF treatments for sight-threatening diabetic eye disease.
- Trial name
- VEGF (NCT01196325)
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Neovascular Age-related Macular Degeneration
Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
Several studies during the last years reported the involvement of anti-retinal autoantibodies in ocular disorders, such as AMD. These studies support the growing evidence of an immunological involvement in the pathogenesis of…
- Trial name
- CAPTAIN (NCT02843490)
- Testing
- Ranibizumab
- Where
- Germany
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
Age-Related Macular Degeneration
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with exudative AMD.
- Trial name
- NCT00423189
- Testing
- Ranibizumab (Lucentis), 0.5mg ranibizumab
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- David M. Brown, M.D.
Retinopathy of Prematurity, Neurodevelopmental Abnormality
Analysis of Ocular and Neurodevelopmental Function for Retinopathy of Prematurity
The goal of this research project is to identify the long-term outcome of neurodevelopment in patients with retinopathy of prematurity(ROP) and the treatment of anti-vascular endothelial growth factor (VEGF) such as intravitreal…
- Trial name
- NCT05186155
- Testing
- Severe ROP
- Where
- Taiwan
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Ocular Histoplasmosis Syndrome
Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome
The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.
- Trial name
- IVL for OHS (NCT00955630)
- Testing
- ranibizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Kentucky
Diabetic Macular Edema, Hard Lipid Exudates
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
- Trial name
- NCT02448446
- Testing
- ranibizumab 0.3mg
- Where
- 4 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- South Coast Retina Center; Carson, McBeath, Boswell, Inc.
Retinal Vein Occlusion
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
- Trial name
- NCT00403039
- Testing
- Ranibizumab (Lucentis )
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Vitreous -Retina- Macula Consultants of New York
Age-Related Macular Degeneration
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing.
- Trial name
- NCT02291887
- Testing
- Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Associated Retinal Consultants, Michigan
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Glaucoma, Rubeosis Iridis
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. To determine and compare whether intraocular aflibercept and ranibizumab decreases rubeosis iridis (RI) in…
- Trial name
- NCT02641457
- Testing
- Aflibercept, Ranibizumab
- Where
- Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Macular Edema, Central Retinal Vein Occlusion
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
CRVO occurs when the vessels in the back of the eye become blocked. This creates a dangerous condition because the vessels are weak and prone to leakage. This results in the development of macular edema.
- Trial name
- ORION (NCT01827722)
- Testing
- Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN
- Where
- 5 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Valley Retina Institute
Myopic Choroidal Neovascularization
Ranibizumab for Myopic Neovascularization
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT01246089
- Testing
- ranibizumab injection
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania